For help on how to get the results you want, see our search tips.
2394 results
Categories
Human Remove Human filter
-
List item
Orphan designation: (1S,3S)-3-amino-4-(difluoromethylene) cyclopentanecarboxylic acid hydrochloride for: Treatment of West syndrome
Date of first decision: 09/02/2012, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Rovalpituzumab tesirine for: Treatment of small cell lung cancer
Date of first decision: 30/05/2016, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of primary hyperoxaluria
Date of first decision: 17/02/2006, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of short bowel syndrome
Date of first decision: 15/10/2014, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Somapacitan for: Treatment of growth hormone deficiency
Date of first decision: 24/08/2018, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: pemigatinib for: Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK
Date of first decision: 17/10/2019, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: Clofazimine for: Treatment of nontuberculous mycobacterial lung disease
Date of first decision: 21/08/2019, Positive, Last updated: 28/01/2021 -
List item
Orphan designation: Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19) for: Treatment of mantle cell lymphoma
Date of first decision: 13/11/2019, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for: Treatment of blastic plasmacytoid dendritic cell neoplasm
Date of first decision: 11/11/2015, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: Oxytocin for: Treatment of Prader-Willi syndrome
Date of first decision: 29/07/2014, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: dimethyl fumarate for: Adjunctive treatment in haematopoietic cell transplantation
Date of first decision: 21/03/2018, Positive, Last updated: 15/01/2021 -
List item
Orphan designation: rasagiline for: Treatment of Duchenne muscular dystrophy
Date of first decision: 28/06/2019, Withdrawn, Last updated: 12/01/2021 -
List item
Orphan designation: Tetrahydrobiopterin for: Treatment of hyperphenylalaninaemia
Date of first decision: 08/06/2004, Withdrawn, Last updated: 11/01/2021 -
List item
Orphan designation: Fenfluramine hydrochloride for: Treatment of Dravet syndrome
Date of first decision: 18/12/2013, Positive, Last updated: 08/01/2021 -
List item
Orphan designation: adeno-associated viral vector serotype 2 containing the human REP1 gene (timrepigene emparvovec) for: Treatment of spinal muscular atrophy
Date of first decision: 24/08/2018, Withdrawn, Last updated: 07/01/2021 -
List item
Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA for: treatment of metachromatic leukodystrophy
Date of first decision: 13/04/2007, Positive, Last updated: 22/12/2020 -
List item
Orphan designation: Miransertib for: Treatment of Proteus syndrome
Date of first decision: 21/03/2018, Positive, Last updated: 22/12/2020 -
List item
Orphan designation: Obeticholic acid for: Treatment of primary sclerosing cholangitis
Date of first decision: 16/03/2014, Positive, Last updated: 22/12/2020 -
List item
Orphan designation: Ibutamoren mesilate for: Treatment of growth hormone deficiency
Date of first decision: 20/06/2017, Positive, Last updated: 22/12/2020 -
List item
Orphan designation: Bardoxolone methyl for: Treatment of Alport syndrome
Date of first decision: 25/05/2018, Positive, Last updated: 21/12/2020 -
List item
Orphan designation: Antisense oligonucleotide targeting the F508delta mutation of CFTR (eluforsen) for: Treatment of cystic fibrosis
Date of first decision: 07/10/2013, Withdrawn, Last updated: 18/12/2020 -
List item
Orphan designation: 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanifibranor) for: Treatment of systemic sclerosis
Date of first decision: 19/11/2014, Withdrawn, Last updated: 14/12/2020 -
List item
Orphan designation: 5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate] for: Treatment of biliary tract cancer
Date of first decision: 16/10/2017, Withdrawn, Last updated: 11/12/2020 -
List item
Orphan designation: Recombinant antibody derivative against human CD19 and CD3 (blinatumomab) for: Treatment of chronic lymphocytic leukaemia
Date of first decision: 01/12/2003, Withdrawn, Last updated: 11/12/2020 -
List item
Orphan designation: Recombinant antibody derivative against human CD19 and CD3 (blinatumomab) for: Treatment of mantle cell lymphoma
Date of first decision: 01/12/2003, Withdrawn, Last updated: 11/12/2020